LEAP THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.51 USD | -2.33% |
|
-8.73% | -39.45% |
Presenter SpeechDouglas Onsi (Executives)Good afternoon. I'm Doug Onsi, the President and CEO ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Calendar
2024-08-08
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.51
USD
Average target price
11.38
USD
Spread / Average Target
+353.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -39.45% | 98.34M | |
| +8.63% | 115B | |
| +13.17% | 107B | |
| -12.76% | 22.31B | |
| -3.99% | 21.6B | |
| -7.19% | 18.23B | |
| -39.93% | 17.62B | |
| +6.67% | 14.26B | |
| +33.90% | 12.37B | |
| -28.60% | 8.28B |
- Stock Market
- Equities
- LPTX Stock
- News Leap Therapeutics, Inc.
- Transcript : Leap Therapeutics, Inc. Presents at 39th Annual JPMorgan Virtual Healthcare Conference, Jan-14-2021 12